Tags

Type your tag names separated by a space and hit enter

Instability of immunophenotype in plasma cell myeloma.
Am J Clin Pathol. 2008 Jun; 129(6):926-33.AJ

Abstract

Little information has been reported describing antigen stability in plasma cell myeloma. In this study, the expression frequency and stability of 2 potential therapeutic targets, CD20 and CD52, along with the frequently aberrantly expressed CD56 antigen, were evaluated by flow cytometric analyses in 56 patients with plasma cell myeloma. Of the 56 patients, 23 (41%) showed immunophenotype change, including CD56 in 6 cases, CD20 in 7 cases, and CD52 in 17 cases. Combined CD56/CD52 change was seen in 3 cases and combined CD20/CD52 in 4 cases. No correlation was found between immunophenotype change and age, sex, stage, plasma cell morphologic features, extent of marrow involvement, time between analyses, type of therapy, or response to therapy. Immunophenotype shift was more common in patients with IgA than in patients with IgG paraprotein. Recognition of lack of stability in immunophenotype may be important, especially in antigen-directed treatment decisions and when specific phenotypes are used to detect residual disease.

Authors+Show Affiliations

Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18480010

Citation

Cao, Wenqing, et al. "Instability of Immunophenotype in Plasma Cell Myeloma." American Journal of Clinical Pathology, vol. 129, no. 6, 2008, pp. 926-33.
Cao W, Goolsby CL, Nelson BP, et al. Instability of immunophenotype in plasma cell myeloma. Am J Clin Pathol. 2008;129(6):926-33.
Cao, W., Goolsby, C. L., Nelson, B. P., Singhal, S., Mehta, J., & Peterson, L. C. (2008). Instability of immunophenotype in plasma cell myeloma. American Journal of Clinical Pathology, 129(6), 926-33. https://doi.org/10.1309/8UVF7YQ1D4D4ETQV
Cao W, et al. Instability of Immunophenotype in Plasma Cell Myeloma. Am J Clin Pathol. 2008;129(6):926-33. PubMed PMID: 18480010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Instability of immunophenotype in plasma cell myeloma. AU - Cao,Wenqing, AU - Goolsby,Charles L, AU - Nelson,Beverly P, AU - Singhal,Seema, AU - Mehta,Jayesh, AU - Peterson,Loann C, PY - 2008/5/16/pubmed PY - 2008/7/2/medline PY - 2008/5/16/entrez SP - 926 EP - 33 JF - American journal of clinical pathology JO - Am. J. Clin. Pathol. VL - 129 IS - 6 N2 - Little information has been reported describing antigen stability in plasma cell myeloma. In this study, the expression frequency and stability of 2 potential therapeutic targets, CD20 and CD52, along with the frequently aberrantly expressed CD56 antigen, were evaluated by flow cytometric analyses in 56 patients with plasma cell myeloma. Of the 56 patients, 23 (41%) showed immunophenotype change, including CD56 in 6 cases, CD20 in 7 cases, and CD52 in 17 cases. Combined CD56/CD52 change was seen in 3 cases and combined CD20/CD52 in 4 cases. No correlation was found between immunophenotype change and age, sex, stage, plasma cell morphologic features, extent of marrow involvement, time between analyses, type of therapy, or response to therapy. Immunophenotype shift was more common in patients with IgA than in patients with IgG paraprotein. Recognition of lack of stability in immunophenotype may be important, especially in antigen-directed treatment decisions and when specific phenotypes are used to detect residual disease. SN - 0002-9173 UR - https://www.unboundmedicine.com/medline/citation/18480010/Instability_of_immunophenotype_in_plasma_cell_myeloma_ L2 - https://academic.oup.com/ajcp/article-lookup/doi/10.1309/8UVF7YQ1D4D4ETQV DB - PRIME DP - Unbound Medicine ER -